moneyheap
ALC · Analysis updated Nov 11, 2026, 4:46 PM ET
Why is Alcon Inc. (ALC) stock moving?
Alcon rose from about $69 in late October to a high of $77.85 on Nov 4. It then slid into Q3 results on Nov 10. Core EPS of $0.91 (+15%) beat estimates, while sales of $2.72B (+5%) were slightly below consensus. Management tightened 2026 sales growth to about 6% and core EPS growth to 12-14%, from 12-15%. It said its markets grew only about 3%, at the low end of assumptions, and pointed to US intraocular lens competition. About $60M of tariff refunds and a $15M milestone payment were non-recurring, and there was no 2027 guidance. Management also said it expects similarly modest market growth next year and sees long-term growth at the bottom of its 6-8% target range. The stock closed at $72.46 on Nov 11, down about 2.2% from $74.06, after a volume of about 4.8M shares. That follows 5.3M shares on Nov 10, and it puts the price back near the late-October to early-November range. Analysts remain broadly positive: the average rating is Buy with a target near $84, though Jefferies has trimmed its target. Product launches, margin expansion and the Neurotech retinal acquisition (ENCELTO peak sales target of $250M-$400M) support the longer-term story. Near term, soft market growth, competition and the lack of 2027 visibility weigh on sentiment.
News behind the analysis
- Innovation and Product Launch Momentum Drive Alcon's Third-Quarter 2026 GrowthQ3 sales were $2.7B, up 5%, with core diluted EPS of $0.91, up 15%. Alcon returned $748M to shareholders year to date and announced the Neurotech acquisition.
- Earnings call transcript: Alcon Q3 2026 beats EPS but shares fall 4.6%Core EPS of $0.91 beat the $0.878 estimate, while revenue of $2.72B was just under the $2.73B forecast. The call also covered $60M of non-recurring tariff refunds.
- Alcon Q3 2026 Earnings Call TranscriptManagement said its markets grew about 3% in Q3, at the low end of its assumptions. It maintained 2026 guidance despite competitive pressures.
- Alcon outlines 2026 sales growth of ~6% and 12%-14% core EPS growth while targeting $250M-$400M ENCELTO peak salesManagement expects ENCELTO peak sales of $250M-$400M. The ramp depends on patient identification and reimbursement.
- Alcon (ALC) Q3 2026 Earnings: Sales Rise 5% to $2.7 BillionFull-year sales growth was tightened to about 6%. Core EPS growth guidance narrowed to 12%-14%, and the report noted a PowerVision write-down.
- Alcon (ALC) Q3 2026 Earnings Call Transcript and SummaryManagement gave no 2027 guidance and expects similarly modest market growth next year. It sees long-term growth at the bottom of its 6%-8% target range.
- Alcon Q3 2026 results press releaseThe guidance table shows sales growth tightened to about 6% from 5%-7%. Core EPS growth moved to 12%-14% from 12%-15%.
- Alcon Q3 2026 results (Business Wire)Core EPS growth guidance was narrowed to a 12%-14% range. Nine-month net income was $449M.
- Alcon (ALC) Stock Price & OverviewThe average analyst rating is Buy, with a 12-month target of $84.45. Jefferies cut its target to $85 from $95.
About Alcon Inc. Ordinary Shares
Alcon is a Swiss eye care company that was spun off from Novartis in 2019. Its shares trade in Zurich and on the NYSE, and it calls itself the global leader in eye care, with a broad range of products for eye surgery and everyday vision care.
How it makes money
Alcon has two segments that each bring in about half of sales. Surgical (about 57% of sales) sells intraocular lenses for cataract surgery, surgical equipment and consumables, and devices for retina and refractive surgery. Vision Care (about 43%) sells contact lenses and ocular health products such as Systane eye drops and the dry-eye treatment Tryptyr. Sales in the first half of 2026 were about $5.5 billion, up roughly 9% from a year earlier.
What usually moves ALC
- Cataract surgery volumes and demand for premium lenses
- Uptake of new products like Tryptyr and the Unity surgical systems
- Contact lens market competition and pricing
- Tariffs and currency swings (it reports in US dollars and is based in Switzerland)
- Pipeline setbacks and impairments, such as the 2026 PowerVision write-down